Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

643
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

26
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma.

Blood cancer journal·2026
Same author

Monoclonal gammopathy of clinical significance: a multisystem review.

Blood cancer journal·2026
Same author

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey.

Blood cancer journal·2026
Same author

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.

Blood cancer journal·2026
Same journal

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Blood cancer journal·2026
Same journal

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Blood cancer journal·2026
Same journal

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same journal

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Blood cancer journal·2026
Same journal

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Blood cancer journal·2026
See all related articles

Related Experiment Video

Updated: Aug 29, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Smoldering multiple myeloma current treatment algorithms.

S Vincent Rajkumar1, Shaji Kumar2, Sagar Lonial3

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.

Blood Cancer Journal
|September 5, 2022
PubMed
Summary
This summary is machine-generated.

Smoldering multiple myeloma (SMM) is a condition with patients either having pre-malignancy or biologic malignancy. High-risk SMM patients benefit from lenalidomide-based therapy, while low-risk SMM patients require observation.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

548

Related Experiment Videos

Last Updated: Aug 29, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

548

Area of Science:

  • Hematology
  • Oncology
  • Plasma Cell Disorders

Background:

  • Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder.
  • SMM exists between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).
  • SMM is clinically heterogeneous, comprising patients with MGUS or MM, lacking a definitive distinguishing feature.

Purpose of the Study:

  • To define risk stratification for SMM patients.
  • To guide therapeutic decisions for high-risk SMM.
  • To establish observation protocols for low-risk SMM.

Main Methods:

  • Clinical risk factors are utilized to identify high-risk SMM.
  • Therapeutic recommendations are based on risk stratification.
  • Observation schedules are defined for low-risk SMM.

Main Results:

  • No single marker reliably differentiates SMM subgroups.
  • High-risk SMM patients have likely undergone malignant transformation.
  • Low-risk SMM patients are considered pre-malignant.

Conclusions:

  • High-risk SMM patients should receive lenalidomide or lenalidomide plus dexamethasone therapy for 2 years.
  • Clinical trial enrollment is an option for newly diagnosed high-risk SMM.
  • Low-risk SMM patients should be monitored every 3-4 months without treatment.